Niacinamide may alleviate systemic scleroris (scleroderma) and Raynaud syndrome
-
This is a very important study, at least to me, for two main reasons. First, it once again demonstrates that two “mysterious” and serious conditions of “idiopathic” origin are little more than mitochondrial function in disguise. Second, it may have implications way beyond those two conditions since the latter one (Raynaud’s) is a very often a symptoms of undiagnosed cancer. If humble niacinamide can ameliorate those two conditions, it may very well be helpful for cancer too. The dosage of niacinamide was on the high end but way below the 3g daily dose beyond which liver problems may occur in humans. The trial used 500mg of niacinamide taken twice daily (1g total faily), for a period of just 2 weeks! It is very hard to imagine that the benefits would not have been much more pronounced had the trial lasted longer.
https://doi.org/10.1002/acr2.90106
Vitamin B3 may improve blood vessels in scleroderma-related Raynaud’s
“…Oral treatment with vitamin B3 for a couple of weeks may reduce abnormalities in tiny blood vessels of people with scleroderma who have Raynaud’s phenomenon, a small study suggests. After two weeks of supplementation, participants showed more normal and fewer giant blood vessels under the fingernails, although these changes did not translate into meaningful symptom reduction or improved quality of life. According to researchers, “the more limited subjective response in scleroderma-related [Raynaud’s] may reflect reduced vasodilatory [blood vessel widening] responsiveness in the context of established structural vascular disease.””
-
@haidut said: ... it may very well be helpful for cancer too.
The reason to use B3 in this study was explained, in part, by its prior use for skin cancer prevention: "In a phase III randomized, placebo-controlled trial by Chen et al, [8] oral nicotinamide administered at 500 mg BD for 12 months was safe and effective in reducing the incidence of nonmelanoma skin cancer and actinic keratoses in individuals who were at high risk. "
[8] Chen AC, Martin AJ, Choy B, et al. A phase 3 randomised trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015; 373(17):1618–1626. doi: https://doi.org/10.1056/NEJMoa1506197
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Register Login